Claudio Nessi

Claudio Nessi is a Managing Director of Omega Funds and Managing Partner at NeoMed. He has over 20 years experience of venture capital investing in healthcare in Europe and the US. He has academic research experience in molecular biology from the Max Planck Institute and the University of Connecticut and has authored scientific articles in the fields of genetics, microbiology and structural biology. Claudio has been an investor in and a board member of many successful emerging life sciences companies including Axovan AG (sold to Actelion), Endosense SA (sold to St. Jude), PregLem SA (sold to Gedeon Richter), Chord Therapeutics (sold to Merck Serono), and Avitide Inc (sold to Repligen). Claudio Nessi holds an MBA from Erasmus University, the Netherlands, and a Ph.D. degree in Genetics from the University of Pavia, Italy. He graduated with a Master in Biology from Lausanne University, Switzerland.